Abstract
Over the last decade several pharmacological approaches for acute heart failure have been introduced, however, no drastic change in the medical management apart from device-dependent therapy was observed. Essentially vasodilators and diuretics as primary therapy in acute heart failure was discussed and encouraged in the guidelines but no breakthrough in the treatment of acute heart failure was achieved. More recently, clinical trials of relaxin and its recombinant form, i.e., serelaxin in patients with acute heart failure demonstrated a significant clinical improvement with favorable safety and tolerability profile in symptomatic heart failure patients. This report reviews the potential beneficial effects and role of serelaxin in the setting of acute heart failure.
Keywords: Acute heart failure, cardiac failure, cardiovascular diseases, cognitive impairment, dyspnea, hospitalized patients, ischemic cardiomyopathy, non-ischemic cardiomyopathy, relaxin, serelaxin, vasodilator.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Serelaxin: New Investigational Treatment in Acute Heart Failure
Volume: 11 Issue: 3
Author(s): Sarmad Said and Debabrata Mukherjee
Affiliation:
Keywords: Acute heart failure, cardiac failure, cardiovascular diseases, cognitive impairment, dyspnea, hospitalized patients, ischemic cardiomyopathy, non-ischemic cardiomyopathy, relaxin, serelaxin, vasodilator.
Abstract: Over the last decade several pharmacological approaches for acute heart failure have been introduced, however, no drastic change in the medical management apart from device-dependent therapy was observed. Essentially vasodilators and diuretics as primary therapy in acute heart failure was discussed and encouraged in the guidelines but no breakthrough in the treatment of acute heart failure was achieved. More recently, clinical trials of relaxin and its recombinant form, i.e., serelaxin in patients with acute heart failure demonstrated a significant clinical improvement with favorable safety and tolerability profile in symptomatic heart failure patients. This report reviews the potential beneficial effects and role of serelaxin in the setting of acute heart failure.
Export Options
About this article
Cite this article as:
Said Sarmad and Mukherjee Debabrata, Serelaxin: New Investigational Treatment in Acute Heart Failure, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (3) . https://dx.doi.org/10.2174/1871525711666131128144132
DOI https://dx.doi.org/10.2174/1871525711666131128144132 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
Current Vascular Pharmacology Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Plant Polyphenols and Oral Health: Old Phytochemicals for New Fields
Current Medicinal Chemistry Effects of Diabetes on Murine Lipoproteins and Vascular Disease
Current Drug Targets Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Roles of SUMOylation in Heart Development and Cardiovascular Diseases
Current Molecular Medicine Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry C-type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target
Current Pharmaceutical Design Antioxidant Capacity, Phytochemical Analysis and Identification of Active Compounds in Anchomanes difformis
The Natural Products Journal Snake Venom Proteins and Peptides as Novel Antibiotics Against Microbial Infections
Current Proteomics Statins for the Prevention of First or Recurrent Stroke
Current Vascular Pharmacology Efficacy of Cangrelor as Bridging Therapy Post PCI
Cardiovascular & Hematological Disorders-Drug Targets Cardiac and Metabolic Consequences of Aerobic Exercise Training in Experimental Diabetes
Current Diabetes Reviews mTOR in Growth and Protection of Hypertrophying Myocardium
Cardiovascular & Hematological Agents in Medicinal Chemistry The Mevalonate Pathway as a Therapeutic Target in the Ph-Negative Chronic Myeloproliferative Disorders
Current Drug Targets Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology Xanthones from Mangosteen Extracts as Natural Chemopreventive Agents: Potential Anticancer Drugs
Current Molecular Medicine